MedPage Today) — PARIS — Treatment with a PD-L1 inhibitor held a survival advantage over single-agent chemotherapy for unfit non-small cell lung cancer (NSCLC) patients ineligible for platinum doublets, findings from the IPSOS trial showed…
Read More
